Literature DB >> 10836134

Simulation of clinical trials.

N H Holford1, H C Kimko, J P Monteleone, C C Peck.   

Abstract

Computer simulation of clinical trials has evolved over the past two decades from a simple instructive game to "full" simulation models yielding pharmacologically sound, realistic trial outcomes. The need to make drug development more efficient and informative and the awareness that many industries make extensive use of simulation in product development have advanced considerably the use of simulation of clinical trials in pharmaceutical product development over the past decade. The structural and stochastic components of trial simulation models are explained as a prelude to a listing of representative simulation projects, reflecting investigative applications of statistical methods, trial design comparisons, and full simulation of new drugs being developed. Lessons learned from these projects are reviewed in the context of their current impact and potential for influencing the future of drug development.

Mesh:

Year:  2000        PMID: 10836134     DOI: 10.1146/annurev.pharmtox.40.1.209

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  68 in total

1.  A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.

Authors:  E H Cox; C Veyrat-Follet; S L Beal; E Fuseau; S Kenkare; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

2.  A brief introduction to Monte Carlo simulation.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 3.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Authors:  L J Lesko; M Rowland; C C Peck; T F Blaschke
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

Review 4.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

Authors:  D A Hughes; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.

Authors:  J V Gobburu; P J Marroum
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.

Authors:  I Nestorov; G Graham; S Duffull; L Aarons; E Fuseau; P Coates
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.

Authors:  Peter A Lockwood; Jack A Cook; Wayne E Ewy; Jaap W Mandema
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 10.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.